Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
:CATX
[203Pb]Pb-Psv359, [212Pb]Pb-Psv359
Ovarian Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Sarcoma, Gastric Cancer, Esophageal Cancer, Head And Neck Cancer, Mesothelioma
Phase I/II
Recruiting
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Nov 25, 2024
―
Nivolumab, [203Pb]Vmt01, [212Pb]Vmt01
Metastatic Melanoma, Melanoma Stage Iii, Melanoma Stage Iv, Recurrent Melanoma (Skin)
Phase I/II
Recruiting
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Nov 15, 2022
―
[203Pb]Vmt-Α-Net, [212Pb]Vmt-Α-Net
Gastroenteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Bronchial Neuroendocrine Tumor, Paraganglioma, Pheochromocytoma
Phase I/II
Recruiting
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
Nov 15, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Perspective Therapeutics (CATX) have in its pipeline
CATX is currently developing the following drugs: [203Pb]Pb-Psv359, [212Pb]Pb-Psv359, Nivolumab, [203Pb]Vmt01, [212Pb]Vmt01, [203Pb]Vmt-Α-Net, [212Pb]Vmt-Α-Net. These drug candidates are in various stages of clinical development as the company works toward FDA approval.